Dusa pharmaceuticals inc (DUSA)
CashFlow / TTM
Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Net income

3,733

8,661

7,587

7,319

0

0

0

Less: income from discontinued operations

-

-

-560

-526

0

0

0

Net income from continuing operations

9,753

8,815

7,026

6,793

0

0

0

Accretion of premiums and discounts on marketable securities

-0

2

7

13

0

0

0

Share-based compensation

2,175

1,817

1,460

1,207

0

0

0

Depreciation and amortization

555

530

501

445

0

0

0

Loss on change in fair value of warrants

-2,826

1,444

-748

-1,013

0

0

0

Deferred revenues recognized

15

1,531

1,612

1,728

0

0

0

Accounts receivable

580

531

715

504

0

0

0

Inventory

824

465

781

775

0

0

0

Prepaid and other assets

150

-86

50

26

0

0

0

Accounts payable, accrued compensation and other accrued expenses

0

0

0

-

0

0

0

Other liabilities

-24

-22

-20

-23

0

0

0

NET CASH PROVIDED BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS

9,322

8,585

7,878

7,629

0

0

0

NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES FROM DISCONTINUED OPERATIONS

-584

-386

-196

409

0

0

0

NET CASH PROVIDED BY OPERATING ACTIVITIES

8,738

8,199

7,682

8,039

0

0

0

Purchases of marketable securities

-

-

-

4,497

0

0

0

Proceeds from maturities and sales of marketable securities

-

-

-

11,430

0

0

0

Restricted cash

0

0

0

1

0

0

0

Purchases of property, plant and equipment

688

738

570

463

0

0

0

NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES

-3,171

-2,171

4,959

7,217

0

0

0

Stock option exercises

376

298

626

516

0

0

0

Settlements of restricted stock for tax withholding obligations

508

508

506

233

0

0

0

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

-132

-210

119

282

0

0

0

NET INCREASE IN CASH AND CASH EQUIVALENTS

5,434

5,817

12,762

15,539

0

0

0

Decrease (increase) in cash and cash equivalents from discontinued operations

0

0

0

-

0

0

0

Increase in cash and cash equivalents from continuing operations

6,019

6,203

12,208

14,379

0

0

0

Accrued capital expenditures

-

-

0

-

-

-

-